Tevogen Bio Establishes Philadelphia R&D Center to Expedite Product Development in Oncology, Neurology, and Virology

  Tevogen Bio Establishes Philadelphia R&D Center to Expedite Product Development in Oncology, Neurology, and Virology   Tevogen Bio’s new Research and Development Center is located in Philadelphia’s Wanamaker Office Building Strategic location of the R&D Center compliments Tevogen’s research facility at CIC Philadelphia as the company expands its precision T cell product pipeline inContinue reading “Tevogen Bio Establishes Philadelphia R&D Center to Expedite Product Development in Oncology, Neurology, and Virology”

Tevogen Bio Appoints Distinguished Clinician and Former Matheny President and CEO, Dr. Kendell R. Sprott, to Corporate Advisory Board

  Tevogen Bio Appoints Distinguished Clinician and Former Matheny President and CEO, Dr. Kendell R. Sprott, to Corporate Advisory Board   Tevogen’s Corporate Advisory Board represents renowned experts from all sectors of the healthcare system, academia, financial industry, and patient advocates to provide guidance as the company continues to expand its genetically unmodified precision TContinue reading “Tevogen Bio Appoints Distinguished Clinician and Former Matheny President and CEO, Dr. Kendell R. Sprott, to Corporate Advisory Board”

Tevogen Bio Initiates Final Dose Level in Proof-of-Concept Clinical Trial of its Investigational T cell Therapy for High-Risk COVID-19 Patients

  Tevogen Bio Initiates Final Dose Level in Proof-of-Concept Clinical Trial of its Investigational T cell Therapy for High-Risk COVID-19 Patients   Trial has advanced to the fourth and final dose escalation cohort with no dose-limiting toxicities observed to-date   Tevogen’s investigational T cell product is genetically unmodified and target-specific   The enrollment is expectedContinue reading “Tevogen Bio Initiates Final Dose Level in Proof-of-Concept Clinical Trial of its Investigational T cell Therapy for High-Risk COVID-19 Patients”

Tevogen Bio Expands Research and Development Capacity at CIC Philadelphia to Accommodate its Expanding Product Portfolio

  Tevogen Bio Expands Research and Development Capacity at CIC Philadelphia to Accommodate its Expanding Product Portfolio   Tevogen Bio’s new facilities at CIC Philadelphia will expand the company’s research and development capabilities and will accelerate the advancement of its product pipeline.   Tevogen’s scientists, technicians, and engineers will use the space to help simultaneouslyContinue reading “Tevogen Bio Expands Research and Development Capacity at CIC Philadelphia to Accommodate its Expanding Product Portfolio”

Tevogen Bio Expands Executive Leadership Team to Accelerate Operational Growth and Commercial Readiness

  Tevogen Bio Expands Executive Leadership Team to Accelerate Operational Growth and Commercial Readiness   New Chief Technical Officer, Stephen Chen, and Global Commercial Lead, Sadiq Khan will support the company’s rapid operational growth and commercialization readiness   Tevogen’s Executive Leadership Team is comprised of experts across cell and gene therapeutic disciplines to accelerate theContinue reading “Tevogen Bio Expands Executive Leadership Team to Accelerate Operational Growth and Commercial Readiness”

Tevogen Bio™ Appoints Prominent Industry Leader Susan Podlogar to the Company’s Corporate Advisory Board

  Tevogen Bio™ Appoints Prominent Industry Leader Susan Podlogar to the Company’s Corporate Advisory Board   Tevogen’s Corporate Advisory Board represents distinguished industry leaders, policy experts, and patient advocates to provide guidance as the company continues to expand its next generation Precision T cell Platform Technology   MetLife’s Chief Human Resources Officer Susan Podlogar appointedContinue reading “Tevogen Bio™ Appoints Prominent Industry Leader Susan Podlogar to the Company’s Corporate Advisory Board”

Tevogen Bio Accelerates Growth With New Corporate Hub to Accommodate its Expanding Operations

  Tevogen Bio Accelerates Growth With New Corporate Hub to Accommodate its Expanding Operations   NJ’s well established Biopharma infrastructure and highly skilled workforce will facilitate Tevogen’s growth   The dynamic medical innovation ecosystem of NJ offers significant opportunities to collaborate   Proximity to world-class global transportation hub and Tevogen’s R&D facilities will add furtherContinue reading “Tevogen Bio Accelerates Growth With New Corporate Hub to Accommodate its Expanding Operations”

Tevogen Bio to Study Potential Use of its T cell Technology in Epstein-Barr Virus and Multiple Sclerosis

  Tevogen Bio to Study Potential Use of its T cell Technology in Epstein-Barr Virus and Multiple Sclerosis   January 20, 2022     METUCHEN, N.J.–(BUSINESS WIRE)–Tevogen Bio, a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, today announced its intention to study its proprietary off-the-shelf T cellContinue reading “Tevogen Bio to Study Potential Use of its T cell Technology in Epstein-Barr Virus and Multiple Sclerosis”

Tevogen Bio Announces Positive Safety Data from Second Cohort in Ongoing Proof-of-Concept Clinical Trial of TVGN-489, its Investigational T cell Therapy for Treatment of COVID-19 in High-Risk Patients

  Tevogen Bio Announces Positive Safety Data from Second Cohort in Ongoing Proof-of-Concept Clinical Trial of TVGN-489, its Investigational T cell Therapy for Treatment of COVID-19 in High-Risk Patients   No dose-limiting toxicities reported in first or second cohorts (n=6)   The dosing of patients on dose levels one and two marks the midway pointContinue reading “Tevogen Bio Announces Positive Safety Data from Second Cohort in Ongoing Proof-of-Concept Clinical Trial of TVGN-489, its Investigational T cell Therapy for Treatment of COVID-19 in High-Risk Patients”

Tevogen Bio Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy

  Tevogen Bio Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy   Patented technology allows for manufacturing hundreds of therapeutic doses of Killer T cells (Cytotoxic CD8+ T Lymphocytes) from a single donor   Tevogen’s investigational T cell therapy, TVGN-489, is designed to detect targetsContinue reading “Tevogen Bio Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy”